SCHEMBL4674830

SCHEMBL4674830

O=C(Cc1csc(S(=O)(=O)c2ccccc2)n1)C(=O)c1nn[nH]n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 1/20 0.37
CES1 P23141 1/20 0.35
NCEH1 Q6PIU2 1/20 0.35
ERCC5 P28715 1/20 0.34
FEN1 P39748 1/20 0.34
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
CTPS1 P17812 1/20 0.32
LMNA P02545 1/20 0.32
PDE5A O76074 2/20 0.32
NAMPT P43490 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672470 0.90 KMT2A (0.39) ALDH1A1MEN1KMT2ALMNAKDM4E
SCHEMBL4670925 0.90 KMT2A (0.39) ALDH1A1MEN1KMT2ACTPS1LMNA
SCHEMBL4674883 0.83 ALDH1A1 (0.37) ALDH1A1CYP2C9CYP2C19MEN1KMT2A
SCHEMBL4674556 0.80 LOXL2 (0.41) ALDH1A1CYP2C9CYP2C19CES1NCEH1
SCHEMBL4675587 0.79 LOX (0.39) ALDH1A1CYP2C9CES1NCEH1ERCC5
SCHEMBL4675843 0.79 MMP2 (0.36) ALDH1A1CES1NCEH1ERCC5FEN1
SCHEMBL4679653 0.78 CES1 (0.37) ALDH1A1CYP2C9CYP2C19CES1NCEH1
SCHEMBL4675057 0.78 HDAC1 (0.47) ALDH1A1CES1NCEH1KMT2ALMNA
SCHEMBL4676360 0.78 CES1 (0.36) ALDH1A1CES1NCEH1ERCC5FEN1
SCHEMBL4677580 0.77 CES1 (0.36) ALDH1A1CYP2C9CES1NCEH1ERCC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885CYP2C9 74/4885CYP2C19 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.